Friday the 13th has turned into a horror story for Immutep, whose share price has collapsed after it abandoned a pivotal trial of its LAG-3 drug efti.
Makary pushes for IRB reforms to catch China’s speedy trial starts
The process by which institutional review boards oversee clinical trials needs reforms that are “big and different” so that the US can keep pace with



